The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Cosentyx (secukinumab) is a brand-name injection prescribed for plaque psoriasis and certain types of arthritis. It works to treat these conditions by slowing down an overactive immune system.

The approval was based on data from two phase 3 trials that evaluated the use of Cosentyx in patients 6 to 18 years of age with severe plaque psoriasis who were candidates for systemic therapy. The ...